Pharmacokinetics and Tolerability of LC28-0126, a Novel Necrosis Inhibitor, After Multiple Ascending Doses: A Phase I Randomized, Double-blind, Placebo-controlled Study in Healthy Male Subjects
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Eunwoo | - |
dc.contributor.author | Hwang, Inyoung | - |
dc.contributor.author | Lee, SeungHwan | - |
dc.contributor.author | Oh, Jaeseong | - |
dc.contributor.author | Chung, Hyewon | - |
dc.contributor.author | Jin, Myungwon | - |
dc.contributor.author | Kim, Soon Ha | - |
dc.contributor.author | Yu, Kyung-Sang | - |
dc.date.accessioned | 2021-08-30T13:48:21Z | - |
dc.date.available | 2021-08-30T13:48:21Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2020-10 | - |
dc.identifier.issn | 0149-2918 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/53009 | - |
dc.description.abstract | Purpose: LC28-0126 is a reactive oxygen species scavenger being developed for the treatment of various conditions caused by oxidative stress, such as oral mucositis, graft-versus-host disease, and lethal reperfusion injury in acute myocardial infarction. The aim of this study was to assess the tolerability and pharmacokinetic properties of LC28-0126 with multiple IV administrations in healthy male subjects. Methods: A dose-block-randomized, double-blind, placebo-controlled, multiple ascending-dose study was conducted. Subjects received 3-, 10-, 20-, or 30-mg doses of LC28-0126 or inactive control vehicle, infused over 30 min, once daily for 7 days. Blood and urine samples were collected for pharmacokinetics assessment. Tolerability was assessed by the documentation of adverse events, including abnormal findings on physical examination, vital sign measurements, blood oxygen saturation monitoring, 12-lead ECG, continuous ECG monitoring, and clinical laboratory testing. Findings: A total of 32 subjects completed the study. After multiple dosing, the plasma concentration of LC28-0126 showed a steep decrease after infusion, followed by slow elimination. Systemic exposure of LC28-0126 was increased proportionally to doses ranging from 3 to 30 mg. The accumulation ratios were 2.58-2.79 on multiple dosing. The fractions excreted unchanged in urine were found to be <5%. All reported drug-related adverse events were injection-site reactions, and no serious adverse events were reported. (C) 2020 Elsevier Inc. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER | - |
dc.subject | INDOLE DERIVATIVE NECROX-7 | - |
dc.subject | ROS | - |
dc.subject | CALCIUM | - |
dc.subject | MECHANISMS | - |
dc.title | Pharmacokinetics and Tolerability of LC28-0126, a Novel Necrosis Inhibitor, After Multiple Ascending Doses: A Phase I Randomized, Double-blind, Placebo-controlled Study in Healthy Male Subjects | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Chung, Hyewon | - |
dc.identifier.doi | 10.1016/j.clinthera.2020.08.011 | - |
dc.identifier.scopusid | 2-s2.0-85091492949 | - |
dc.identifier.wosid | 000596677000009 | - |
dc.identifier.bibliographicCitation | CLINICAL THERAPEUTICS, v.42, no.10, pp.1946 - U11 | - |
dc.relation.isPartOf | CLINICAL THERAPEUTICS | - |
dc.citation.title | CLINICAL THERAPEUTICS | - |
dc.citation.volume | 42 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 1946 | - |
dc.citation.endPage | U11 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | INDOLE DERIVATIVE NECROX-7 | - |
dc.subject.keywordPlus | ROS | - |
dc.subject.keywordPlus | CALCIUM | - |
dc.subject.keywordPlus | MECHANISMS | - |
dc.subject.keywordAuthor | clinical trials | - |
dc.subject.keywordAuthor | LC28-0126 | - |
dc.subject.keywordAuthor | pharmacokinetics | - |
dc.subject.keywordAuthor | Phase I | - |
dc.subject.keywordAuthor | tolerability | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.